394 related articles for article (PubMed ID: 25698233)
21. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
22. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.
Ekblad E; Jongsma H; Brabet P; Bockaert J; Sundler F
Ann N Y Acad Sci; 2000; 921():137-47. PubMed ID: 11193817
[TBL] [Abstract][Full Text] [Related]
23. VIP and PACAP analogs regulate therapeutic targets in high-risk neuroblastoma cells.
de Boisvilliers M; Perrin F; Hebache S; Balandre AC; Bensalma S; Garnier A; Vaudry D; Fournier A; Festy F; Muller JM; Chadéneau C
Peptides; 2016 Apr; 78():30-41. PubMed ID: 26826611
[TBL] [Abstract][Full Text] [Related]
24. Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery.
Tasma Z; Siow A; Harris PWR; Brimble MA; Hay DL; Walker CS
Br J Pharmacol; 2022 Feb; 179(3):435-453. PubMed ID: 34612509
[TBL] [Abstract][Full Text] [Related]
25. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta.
Scaldaferri ML; Modesti A; Palumbo C; Ulisse S; Fabbri A; Piccione E; Frajese G; Moretti C
Endocrinology; 2000 Mar; 141(3):1158-67. PubMed ID: 10698193
[TBL] [Abstract][Full Text] [Related]
26. PACAP/VIP and receptor characterization in micturition pathways in mice with overexpression of NGF in urothelium.
Girard BM; Malley SE; Braas KM; May V; Vizzard MA
J Mol Neurosci; 2010 Nov; 42(3):378-89. PubMed ID: 20449688
[TBL] [Abstract][Full Text] [Related]
27. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
28. PACAP and PAC1 receptor in brain development and behavior.
Shen S; Gehlert DR; Collier DA
Neuropeptides; 2013 Dec; 47(6):421-30. PubMed ID: 24220567
[TBL] [Abstract][Full Text] [Related]
29. Pituitary adenylate cyclase activating polypeptide-mediated intracrine signaling in the testicular germ cells.
Li M; Funahashi H; Mbikay M; Shioda S; Arimura A
Endocrine; 2004 Feb; 23(1):59-75. PubMed ID: 15034198
[TBL] [Abstract][Full Text] [Related]
30. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
[TBL] [Abstract][Full Text] [Related]
31. Macrophage Resistance to HIV-1 Infection Is Enhanced by the Neuropeptides VIP and PACAP.
Temerozo JR; Joaquim R; Regis EG; Savino W; Bou-Habib DC
PLoS One; 2013; 8(6):e67701. PubMed ID: 23818986
[TBL] [Abstract][Full Text] [Related]
32. Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice.
Ivic I; Fulop BD; Juhasz T; Reglodi D; Toth G; Hashimoto H; Tamas A; Koller A
J Vasc Res; 2017; 54(3):180-192. PubMed ID: 28490016
[TBL] [Abstract][Full Text] [Related]
33. PACAP and its receptors in cranial arteries and mast cells.
Jansen-Olesen I; Hougaard Pedersen S
J Headache Pain; 2018 Feb; 19(1):16. PubMed ID: 29460121
[TBL] [Abstract][Full Text] [Related]
34. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.
Vaudry D; Gonzalez BJ; Basille M; Yon L; Fournier A; Vaudry H
Pharmacol Rev; 2000 Jun; 52(2):269-324. PubMed ID: 10835102
[TBL] [Abstract][Full Text] [Related]
35. Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats.
Giunta S; Castorina A; Bucolo C; Magro G; Drago F; D'Agata V
Peptides; 2012 Sep; 37(1):32-9. PubMed ID: 22721946
[TBL] [Abstract][Full Text] [Related]
36. PAC1- and VPAC2 receptors in light regulated behavior and physiology: Studies in single and double mutant mice.
Hannibal J; Georg B; Fahrenkrug J
PLoS One; 2017; 12(11):e0188166. PubMed ID: 29155851
[TBL] [Abstract][Full Text] [Related]
37. Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.
Cunha-Reis D; Aidil-Carvalho Mde F; Ribeiro JA
Hippocampus; 2014 Nov; 24(11):1353-63. PubMed ID: 24935659
[TBL] [Abstract][Full Text] [Related]
38. Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats.
Koga M; Mizuno Y; Watanabe I; Kawakami H; Goto T
J Appl Physiol (1985); 2014 Aug; 117(4):383-91. PubMed ID: 24947028
[TBL] [Abstract][Full Text] [Related]
39. [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system].
Hashimoto H
Yakugaku Zasshi; 2002 Dec; 122(12):1109-21. PubMed ID: 12510388
[TBL] [Abstract][Full Text] [Related]
40. Novel splice variants of type I pituitary adenylate cyclase-activating polypeptide receptor in frog exhibit altered adenylate cyclase stimulation and differential relative abundance.
Alexandre D; Vaudry H; Grumolato L; Turquier V; Fournier A; Jégou S; Anouar Y
Endocrinology; 2002 Jul; 143(7):2680-92. PubMed ID: 12072402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
